Zai Lab (ZLAB)

Executive Summary

Zai Lab is a commercial-stage biopharmaceutical company based in China and the US, focused on innovative therapies in oncology, immunology, neuroscience, and infectious disease. With eight approved products generating revenue, the company is advancing a pipeline of novel candidates. Key pipeline assets include ZL-1310, a DLL3-targeting ADC in Phase 3 for small-cell lung cancer (SCLC), and omadacycline-based combination therapy in Phase 3 for community-acquired bacterial pneumonia (CABP). Zai Lab also has early-stage programs in immuno-oncology and dermatology. The company's dual-country operations and proven commercialization capabilities position it for sustained growth, though it faces typical biotech risks including clinical trial outcomes and regulatory approvals. Recent Phase 2 data for its plaque psoriasis candidate ZL-1102 could support further development. Overall, Zai Lab represents a diversified biopharma play with near-term catalysts that could drive significant value.

Upcoming Catalysts (preview)

• Q3 2026ZL-1310 Phase 3 Data Readout in Small-Cell Lung Cancer65% success
• Q4 2026Omadacycline Combination Phase 3 Completion in CABP70% success
• Q2 2026ZL-1102 Phase 2 Top-Line Results in Plaque Psoriasis60% success